1265896-03-4

Basic information

• Product Name: IMidazo[1,2-a]pyrazine-3-carboxylic acid
• Synonyms: IMidazo[1,2-a]pyrazine-3-carboxylic acid
• CAS NO: 1265896-03-4
• Molecular Formula: C7H5N3O2
• Molecular Weight: 163.1335
• Mol File: 1265896-03-4.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Density: 1.58±0.1 g/cm3(Predicted)
• PKA: -1.20±0.41(Predicted)
• CAS DataBase Reference: IMidazo[1,2-a]pyrazine-3-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: IMidazo[1,2-a]pyrazine-3-carboxylic acid(1265896-03-4)
• EPA Substance Registry System: IMidazo[1,2-a]pyrazine-3-carboxylic acid(1265896-03-4)

Safety Data

• Hazardous Substances Data: 1265896-03-4(Hazardous Substances Data)

Usage

General Description

IMidazo[1,2-a]pyrazine-3-carboxylic acid is a chemical compound that belongs to the class of imidazo[1,2-a]pyrazine derivatives. It is an aromatic carboxylic acid with a fused heterocyclic ring structure. IMidazo[1,2-a]pyrazine-3-carboxylic acid has potential pharmacological properties and has been studied for its biological activities, including its role as a drug intermediate in the synthesis of pharmaceutical compounds. Its chemical structure makes it a versatile building block in organic synthesis for the preparation of various heterocyclic compounds. Additionally, it has been studied for its potential applications in medicinal and pharmaceutical research, demonstrating its potential in the development of new drugs and therapeutic agents.

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRα, PDGFRβ) kinases.

COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS

The invention provides compounds of formulae (I) and (II) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of c-kit or c-kit and PDGFR (PDGFRcalpha PDGFRbeta) kinases